Nonalcoholic Fatty Liver Disease (NAFLD) Market (2026-2033) | NAFLD Drugs, NASH Treatment, Obesity Management, Hepatology Research, Metabolic Syndrome Growth, Emerging Drug Pipeline & Market Expansion

DataM Intelligence has unveiled its latest research study, "Nonalcoholic Fatty Liver Disease Market Size 2026," delivering strategic intelligence designed to identify high-growth opportunities, evaluate competitive positioning, and stay ahead of rapidly evolving market trends. The report provides a comprehensive analysis of market size, revenue performance, CAGR projections, regional growth patterns, and detailed segmentation insights, along with an in-depth assessment of the key factors driving industry expansion. It also highlights emerging opportunities, investment hotspots, and the competitive landscape shaping the future of the global Nonalcoholic Fatty Liver Disease market.

Connect with the right partners and unlock new growth opportunities today:- https://www.datamintelligence.com/partner-identification-enquiry/nonalcoholic-fatty-liver-disease-market?kb

United States: Recent Industry Developments

✅ March 2026: Madrigal Pharmaceuticals accelerated commercialization activities for resmetirom-based NASH treatment solutions following increasing physician adoption across the United States.

✅ February 2026: Pfizer Inc. expanded clinical research collaborations focused on combination therapies targeting liver fibrosis and metabolic dysfunction-associated steatohepatitis (MASH).

✅ January 2026: Gilead Sciences advanced late-stage clinical trials evaluating novel anti-fibrotic therapies for patients with progressive NAFLD and NASH conditions.

✅ December 2025: Novo Nordisk strengthened investment in GLP-1-based metabolic disease therapies aimed at addressing obesity-linked fatty liver disease progression.

Download Free Sample Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/nonalcoholic-fatty-liver-disease-market?kb

List of Key Players 2026:

Pfizer Inc., AstraZeneca, Novartis AG, Takeda Pharmaceutical Company Limited., Intercept Pharmaceuticals, Inc., F. Hoffmann-La Roche Ag, Merck & Co., Inc., Abbvie Inc., And Gilead Sciences, Inc.

Key Highlights 2026:

Pfizer Inc. - Holds a 15.6% share, driven by its strong metabolic disease research pipeline, global clinical trial network, and expanding focus on liver disease therapeutics and precision medicine.

AstraZeneca - Holds a 13.8% share, supported by strategic investments in cardiometabolic disorders, advanced biologic therapies, and growing research collaborations targeting NASH and liver fibrosis.

Novartis AG - Holds an 11.9% share, fueled by innovative drug discovery capabilities, strong hepatology research programs, and increasing development of targeted therapies for chronic liver diseases.

Takeda Pharmaceutical Company Limited - Holds a 10.4% share, driven by expanding gastrointestinal and rare disease portfolios, advanced R&D infrastructure, and strategic partnerships in liver disease therapeutics.

Intercept Pharmaceuticals, Inc. - Holds an 8.7% share, supported by its focus on NASH and fibrosis treatment development, regulatory advancements, and commercialization of liver disease therapies.

F. Hoffmann-La Roche AG - Holds a 7.8% share, powered by strong diagnostic capabilities, biomarker-based liver disease monitoring technologies, and robust pharmaceutical innovation in chronic disease management.

Merck & Co., Inc. - Holds a 6.9% share, driven by extensive clinical development programs, immunology expertise, and growing investments in metabolic and inflammatory liver disorders.

AbbVie Inc. - Holds a 5.8% share, supported by advanced biologics research, strategic acquisitions, and expanding therapeutic approaches targeting fibrosis and metabolic dysfunction.

Gilead Sciences, Inc. - Holds a 4.9% share, fueled by strong antiviral and hepatology expertise, innovative liver disease drug candidates, and increasing focus on combination therapies for NASH treatment.

Others - Hold a combined 14.2% share, comprising emerging biotechnology firms and regional pharmaceutical companies advancing novel therapies, fibrosis-targeting drugs, and precision treatment solutions for nonalcoholic fatty liver disease globally.

Key Strategic Growth Forecast Projections 2026:

The Global Nonalcoholic Fatty Liver Disease Market is entering a high-growth phase, with strong momentum expected throughout 2026-2033. Backed by accelerating industry adoption, strategic investments, and continuous innovation from leading players, the market is poised for significant expansion beyond its steady 2025 growth trajectory. The latest outlook highlights emerging opportunities, evolving competitive dynamics, and long-term revenue potential shaping the future of the industry.

Key Strategic Developments 2025-2026:

✅ May 2026: Madrigal Pharmaceuticals expanded commercialization initiatives for resmetirom-based therapy programs targeting patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis, strengthening its metabolic liver disease portfolio.

✅ April 2026: Novo Nordisk increased investment in GLP-1 receptor agonist research for NAFLD and NASH management, focusing on weight reduction and liver fat improvement outcomes in late-stage clinical studies.

✅ March 2026: Pfizer advanced development of metabolic dysfunction-associated steatohepatitis (MASH) therapeutic candidates aimed at reducing liver inflammation and fibrosis progression.

✅ February 2026: Gilead Sciences strengthened collaborations and pipeline expansion activities for NASH therapeutics targeting fibrosis biomarkers and combination treatment approaches.

✅ January 2026: Viking Therapeutics reported continued progress in clinical programs evaluating dual agonist therapies for reducing hepatic fat accumulation and improving metabolic outcomes.

✅ December 2025: AstraZeneca expanded research initiatives focused on precision medicine and biomarker-driven approaches for chronic liver disease and NAFLD patient stratification.

✅ November 2025: Boehringer Ingelheim accelerated clinical evaluation of combination therapies designed to address liver fibrosis, insulin resistance, and inflammatory pathways associated with NAFLD progression.

✅ October 2025: 89bio continued advancement of FGF21 analog therapy programs targeting liver fat reduction and fibrosis improvement in patients with NASH and metabolic liver disorders.

How Our Market Research Process Works:

The global Nonalcoholic Fatty Liver Disease Market research report delivers strategic intelligence built through a robust blend of primary insights and extensive secondary research. The study provides a deep analysis of critical market forces shaping the industry, including regulatory developments, competitive positioning, evolving demand patterns, and historical market performance. It further highlights breakthrough technologies, innovation trends, and advancements across connected industries influencing the future of Nonalcoholic Fatty Liver Disease adoption. The report also uncovers high-growth opportunities, investment potential, market risks, and key operational challenges, enabling businesses to make faster, data-driven decisions in an increasingly competitive landscape.

Funding/M&A/partnerships 2025-2026:

May 2026: Madrigal Pharmaceuticals signed a licensing deal worth up to $1 billion with Arrowhead Pharmaceuticals to strengthen its MASH/NAFLD pipeline.

January 2026: Biopharma companies increased M&A focus on cardiometabolic and MASH assets amid rising demand for fatty liver disease therapies.

September 2025: Roche announced the acquisition of 89bio for up to $3.5 billion to expand its MASH and fatty liver disease portfolio.

October 2025: Novo Nordisk agreed to acquire Akero Therapeutics for up to $5.2 billion to strengthen its MASH treatment pipeline.

May 2025: GSK acquired rights to Boston Pharmaceuticals' efimosfermin alfa in a deal valued up to $2 billion targeting MASH and fatty liver diseases.

Request Strategic Market Customization: https://datamintelligence.com/customize/nonalcoholic-fatty-liver-disease-market?kb

Japan: Recent Industry Developments

✅ March 2026: Takeda Pharmaceutical Company expanded research initiatives for metabolic dysfunction-associated liver disease therapies targeting rising NAFLD prevalence in Japan.

✅ February 2026: Eisai Co., Ltd. collaborated with academic institutions to develop innovative diagnostic biomarkers for early-stage fatty liver disease detection.

✅ January 2026: Mitsubishi Tanabe Pharma advanced clinical development programs focused on liver fibrosis and inflammation reduction therapies.

✅ December 2025: Otsuka Pharmaceutical increased investments in precision medicine approaches for chronic liver disease management and metabolic health improvement.

Major Segments Opportunity 2026:

By Drug Class: Antioxidants, Lipid-Lowering Drugs, Insulin sensitizers, Pentoxifylline, Angiotensin Receptor Blockers, Others

By Disease Stage: Non-Alcoholic Steatohepatitis (NASH), Cirrhosis, Fibrosis

By Route of Administration: Injectable, Oral, Other

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others

Regional Growth Intelligence for Market:

⇥ North America: 41% - Dominates the Nonalcoholic Fatty Liver Disease market due to rising obesity prevalence, increasing diagnosis rates, strong pharmaceutical R&D, and advanced healthcare infrastructure.

⇥ Europe: 27% - Growth is driven by increasing awareness of liver health, expanding clinical research activities, and supportive government healthcare initiatives.

⇥ Asia-Pacific: 21% - Rapid market expansion supported by growing diabetic and obese populations, improving healthcare access, and increasing adoption of advanced therapeutics.

⇥ Middle East & Africa: 6% - Emerging demand fueled by rising lifestyle-related liver disorders and improving healthcare investments across the region.

⇥ South America: 5% - Steady growth supported by increasing awareness of metabolic disorders and expanding access to liver disease treatment options.

Market Drivers 2026:

Rising global prevalence of obesity, diabetes, and metabolic syndrome is significantly driving the growth of the Nonalcoholic Fatty Liver Disease market worldwide.

Increasing awareness regarding early diagnosis and liver health management is accelerating demand for advanced diagnostic imaging and biomarker-based screening solutions.

Growing adoption of sedentary lifestyles, unhealthy dietary habits, and high-calorie food consumption is contributing to the increasing burden of Nonalcoholic Fatty Liver Disease globally.

Advancements in non-invasive diagnostic technologies such as elastography, MRI-PDFF, and serum biomarkers are improving disease detection and patient monitoring capabilities.

Increasing research and development activities focused on novel therapeutics for NASH and liver fibrosis are strengthening market expansion opportunities.

Rising investments by pharmaceutical and biotechnology companies in clinical trials for metabolic liver disorders are supporting innovation in treatment development.

Growing demand for personalized medicine and targeted therapies is further propelling the development of next-generation Nonalcoholic Fatty Liver Disease treatment solutions.

Increasing government initiatives and healthcare awareness campaigns focused on chronic liver diseases are supporting market growth across developed and emerging economies.

Expansion of healthcare infrastructure and improved access to liver disease diagnostics in emerging regions are contributing to increasing patient identification and treatment rates.

Rising emphasis on preventive healthcare, lifestyle modification programs, and weight management solutions is positively influencing market demand globally.

Unlock & Get Full 360° Best Strategic Report: https://www.datamintelligence.com/buy-now-page?report=nonalcoholic-fatty-liver-disease-market?kb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.